A project from the American Society of Retina SpecialistsSign in to view content
Intravitreal Tarcocimab Tedromer for Diabetic Retinopathy: First-time, Primary Endpoint Results from the Phase 3 GLOW2 Trial
- Video
- Published 2026
Related
Category: Diabetic Retinopathy